Literature DB >> 11084747

[Evaluation of the North American Spine Society Instrument for assessment of health status in patients with chronic backache].

O Sangha1, M Wildner, A Peters.   

Abstract

PURPOSE OF THE STUDY: The translation/back and translation and validation of the North American Spine Society (NASS) Instrument in German was published recently. This contribution aims at describing the scoring of this questionnaire.
METHOD: The scoring is oriented on the recommendations of the developing scientists of the US-American original, with whom we cooperated during the German validation.
RESULTS: The scoring algorithm is described, a program for computerized scoring in SPSS was written. Program syntax and the questionnaire are reproduced.
CONCLUSION: The contribution enables interested researchers to apply and score the NASS questionnaire in German-speaking countries.

Entities:  

Mesh:

Year:  2000        PMID: 11084747     DOI: 10.1055/s-2000-10176

Source DB:  PubMed          Journal:  Z Orthop Ihre Grenzgeb        ISSN: 0044-3220


  4 in total

1.  [Optimized assessment of the outcome in patients with radicular back pain of the lumbar spine. The modified NASS questionnaire].

Authors:  M Janousek; S Ferrari; U D Schmid; H A Bischoff; M Balsiger; R Theiler
Journal:  Schmerz       Date:  2011-09       Impact factor: 1.107

2.  Validity and responsiveness of the Core Outcome Measures Index (COMI) for the neck.

Authors:  C D Fankhauser; U Mutter; E Aghayev; A F Mannion
Journal:  Eur Spine J       Date:  2011-08-20       Impact factor: 3.134

3.  German translation, cross-cultural adaptation and validation of the whiplash disability questionnaire.

Authors:  Corina Schuster; Michael McCaskey; Thierry Ettlin
Journal:  Health Qual Life Outcomes       Date:  2013-03-14       Impact factor: 3.186

4.  German version of the whiplash disability questionnaire: reproducibility and responsiveness.

Authors:  Michael McCaskey; Thierry Ettlin; Corina Schuster
Journal:  Health Qual Life Outcomes       Date:  2013-03-08       Impact factor: 3.186

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.